1. Home
  2. AGIO vs BLX Comparison

AGIO vs BLX Comparison

Compare AGIO & BLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$34.45

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Banco Latinoamericano de Comercio Exterior S.A.

BLX

Banco Latinoamericano de Comercio Exterior S.A.

HOLD

Current Price

$56.23

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
BLX
Founded
2007
1977
Country
United States
Panama
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Commercial Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.0B
IPO Year
2013
1997

Fundamental Metrics

Financial Performance
Metric
AGIO
BLX
Price
$34.45
$56.23
Analyst Decision
Buy
Analyst Count
8
0
Target Price
$39.88
N/A
AVG Volume (30 Days)
969.5K
114.6K
Earning Date
04-29-2026
04-27-2026
Dividend Yield
N/A
5.00%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$43,011,000.00
N/A
Revenue This Year
$74.95
$14.22
Revenue Next Year
$165.77
$9.84
P/E Ratio
N/A
$8.26
Revenue Growth
N/A
N/A
52 Week Low
$22.24
$36.52
52 Week High
$46.00
$55.23

Technical Indicators

Market Signals
Indicator
AGIO
BLX
Relative Strength Index (RSI) 66.34 76.53
Support Level $26.64 $42.98
Resistance Level $36.35 N/A
Average True Range (ATR) 1.38 1.06
MACD 0.08 0.45
Stochastic Oscillator 71.17 96.29

Price Performance

Historical Comparison
AGIO
BLX

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

About BLX Banco Latinoamericano de Comercio Exterior S.A.

Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.

Share on Social Networks: